SUZANE KIOKO ONO
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Gastroenterologia, Faculdade de Medicina - Docente
P ICHC, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/07 - Laboratório de Gastroenterologia Clínica e Experimental, Hospital das Clínicas, Faculdade de Medicina
P ICHC, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/07 - Laboratório de Gastroenterologia Clínica e Experimental, Hospital das Clínicas, Faculdade de Medicina
7 resultados
Resultados de Busca
Agora exibindo 1 - 7 de 7
- Novel HBV capsid assembly modulator inhibits pregenomic RNA encapsidation by accelerating capsid assembly kinetics and disrupting core protein dephosphorylation(2019) BASSIT, Leda; VERMA, Kiran; ONO, Suzane Kioko; COX, Bryan; AMBLARD, Franck; SCHINAZI, Raymond F.
conferenceObject 2-YEAR RESULTS OF TELBIVUDINE (LDT) ROADMAP STUDY VERIFY THE OPTIMAL EFFICACY AND SAFETY RESULTS IN HBEAG POSITIVE CHRONIC HEPATITIS B (CHB) PATIENTS(2012) PIRATVISUTH, T.; KOMOLMIT, P.; TANWANDEE, T.; SUKEEPAISARNJAROEN, W.; CHAN, H. L.; PESSOA, M. G.; FASSIO, E.; ONO-NITA, S.; BESSONE, F.; DARUICH, J.; ZEUZEM, S.; CHEINQUER, H.; DONG, Y.; TRYLESINSKI, A.Background and Aims: The roadmap concept based on Week 24 HBV DNA levels was prospectively validated with 1year results of Roadmap study (A2410) as previously reported. The 2 year results are reported here. Patients and Methods: All patients were HBeAg positive and started LDT monotherapy from baseline and Tenofovir (LDT) was added to patients with detectable (≥300 copies/ml) HBV DNA at 24w until 104w. Results: 105 patients were enrolled and 100 patients were eligible for modified ITT (mITT) analysis (1 patient with baseline M204I mutation, 2 lost follow-up and 2 didn’t follow roadmap concept). At 24w, 55 patients achieved undetectable HBV DNA and 45 patients with detectable HBV DNA added with TDF (73% of the 45 patients with baseline HBV DNA > 9log10 copies/ml). At 104w, 94% had undetectable HBV DNA, 50%/44% HBeAg loss/seroconversion, 7%/4% HBsAg loss/seroconversion. One patient in LDT mono-treated arm had Virologic Breakthrough (VB) at Week 72 and detected M204I mutation; achieved undetectable HBV DNA 8wks after TDF add-on. One LDT mono-treated patient had one time of HBV DNA increase of 1 log10 above nadir (assessment ongoing). Both patients had baseline HBV DNA > 9log10 copies/ml. In the overall safety population, Serious Adverse Events (SAEs) was reported in 6/105 (5.7%) patients and all unrelated to treatment. No case of myopathy/myositis was reported. Overall GFR (by MDRD formula) improvement was +6.4 and +8.6ml/min/1.73m2 in LDT mono and LDT+TDF group respectively. In patients with abnormal baseline GFR (60–90ml/min/1.73m2), GFR improvement at 2yr was +12.0 and +1.5ml/min/1.73m2 in LDT and LDT+TDF respectively. 50% and 40% of patients with abnormal baseline GFR (60–90ml/min/1.73m2) in LDT and LDT+TDF group respectively shifted to normal (>90ml/min/1.73m2) at 2yr. Only 1 patient in TDF add-on group had once creatinine increase to 232 μmol/L at Week 96, and returned to 91 μmol/L within 4 days. Conclusion: Telbivudine roadmap with tenofovir add-on at 24 weeks in patients with detectable HBVDNA improved GFR in both LDT and LDT+TDF treated patients, as well as favorable efficacy and safety profiles.conferenceObject Worldwide lack of early referral of patients with alcoholic liver disease: results of the global alcoholic liver disease survey (GLADIS)(2017) SHAH, N. D.; COTS, M. V.; ZHANG, C.; ZAHIRAGIC, N.; YU, Y.; YACOUB, M.; WU, P.; WANDERA, A.; VOROBIOFF, J.; TRAQUINO, E. S. D. S.; THURAIRAJAH, P. H.; TAN, S.; SPRECKIC, S.; SOLER, E. R. A.; SIVAC, N.; SIOW, W.; SCHEURICH, C.; SAEZ-ROYUELA, F.; RODIL, A.; REIS, D.; ONO, S.; NABESHIMA, M.; KIONG, T. E.; KARONEY, M.; GUI, W.; FERNANDEZ, M. C.; FARIAS, A.; DOMECH, C. R.; COSTA, P. M.; BIRYUKOVA, M.; ALFADHLI, A.; YANG, L.; SOME, F.; KOCHHAR, R.; KLUWE, J.; KIM, W.; ISAKOV, V.; HUSIC-SELIMOVIC, A.; HSIANG, J.; GEORGE, J.; KASSAS, M. El; DORTA, Z.; CARRILHO, F. J.; BESSONE, F.; ARANDA, E. B.; ALBORAIE, M.; CORTEZ-PINTO, H.; BATALLER, R.conferenceObject Artificial Intelligence in medical imaging of the liver-a convolutional neural network solution for Computed Tomography exam phases recognition(2021) CORTEZ FILHO, Joao Martins; VIANNA, Luis Gustavo Rocha; CICONELLE, Ana; ROCHA, Bruno Aragao; LEITE, Jean Michel Rocha Sampaio; NOGUEIRA, Lucas Salume Lima; GUIMARAES, Lenon Liberdade Alvares; SILVA FILHO, Mauricio Ricardo Moreira da; FERREIRA, Lorena Carneiro; OLIVEIRA, Brunna; PAIVA, Wesley Borges de; LAZZARO FILHO, Ricardo di; ONO, Suzane KiokoconferenceObject ALLOPURINOL IS SAFE AND EFFECTIVE TO ACHIEVE BIOCHEMICAL AND HISTOLOGICAL REMISSION IN PATIENTS WITH AUTOIMMUNE HEPATITIS WITH INCOMPLETE THERAPEUTIC RESPONSE(2016) TERRABUIO, D. R.; FALCAO, L. T. De Moraes; ONO, S. K.; DINIZ, M. A.; CARRILHO, F. J.; CANCADO, E.conferenceObject Multivariant surface quasispecies in a hepatitis B virus chronically infected individual with concomitant and continually positive surface antigen and anti-HBS biomarkers(2020) ONO, Suzane Kioko; CRAIG, Johanna; BASSIT, Leda; ABREU, Rodrigo; GONZALEZ, Dimitri; CARRILHO, Flair Jose; SCHINAZI, Raymond F.- Novel and potent HBV capsid modulator reduces HBeAg and cccDNA in core site directed T109I mutant in HepNTCP cells(2018) BASSIT, L.; COX, B.; ONO, S. K.; VERMA, K.; YOON, J.; AMBLARD, F.; SCHINAZI, R. F.